MX2014009628A - Uniones a cdim y sus usos. - Google Patents

Uniones a cdim y sus usos.

Info

Publication number
MX2014009628A
MX2014009628A MX2014009628A MX2014009628A MX2014009628A MX 2014009628 A MX2014009628 A MX 2014009628A MX 2014009628 A MX2014009628 A MX 2014009628A MX 2014009628 A MX2014009628 A MX 2014009628A MX 2014009628 A MX2014009628 A MX 2014009628A
Authority
MX
Mexico
Prior art keywords
cdim
binding proteins
cells
well
diagnostic assays
Prior art date
Application number
MX2014009628A
Other languages
English (en)
Other versions
MX363819B (es
Inventor
Nelson N H Teng
Neelima M Bhat
Marcia M Bieber
Bruce A Keyt
Original Assignee
Igm Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc
Publication of MX2014009628A publication Critical patent/MX2014009628A/es
Publication of MX363819B publication Critical patent/MX363819B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente descripción se refiere a proteínas que se unen a una molécula inductora de muerte celular ("CDIM") y a composiciones farmacéuticas de ellas. En particular, la descripción proporciona proteínas de unión a CDIM que son útiles para la disminución y eliminación selectiva de células B, incluidas las células B neoplásicas, así como también células neoplásicas que rio provienen de células B que expresan antígenos de tipo CDIM. Además, la descripción incluye polinucleótidos que codifican las proteínas de unión a antígeno descritas, y sistemas de expresión para producirlas. Además, la presente descripción incluye métodos para tratar a pacientes con enfermedades proliferativas de células B y mediadas por células B mediante la administración de proteínas de unión a CDIM, así como también análisis de diagnóstico para identificar proteínas que se unen a CDIM. La descripción también contempla análisis de diagnóstico para identificar poblaciones de pacientes que se pueden tratar con las proteínas de unión a CDIM.
MX2014009628A 2012-02-08 2013-02-08 Uniones a cdim y sus usos. MX363819B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261633330P 2012-02-08 2012-02-08
PCT/US2013/025430 WO2013120012A2 (en) 2012-02-08 2013-02-08 Cdim binding proteins and uses thereof

Publications (2)

Publication Number Publication Date
MX2014009628A true MX2014009628A (es) 2015-03-19
MX363819B MX363819B (es) 2019-04-03

Family

ID=48045015

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009628A MX363819B (es) 2012-02-08 2013-02-08 Uniones a cdim y sus usos.

Country Status (15)

Country Link
US (1) US9409976B2 (es)
EP (1) EP2812356B1 (es)
JP (1) JP6335796B2 (es)
KR (1) KR102102111B1 (es)
CN (1) CN104254544B (es)
AU (1) AU2013200903B2 (es)
BR (1) BR112014019459B1 (es)
CA (1) CA2863714C (es)
DK (1) DK2812356T3 (es)
ES (1) ES2735289T3 (es)
HK (1) HK1205136A1 (es)
IN (1) IN2014MN01781A (es)
MX (1) MX363819B (es)
TW (1) TWI606064B (es)
WO (1) WO2013120012A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3041862B1 (en) 2013-09-05 2020-05-06 IGM Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
EP3572425A1 (en) 2013-12-17 2019-11-27 AIMM Therapeutics B.V. Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
WO2015120474A1 (en) 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
SG11201608194VA (en) 2014-04-03 2016-10-28 Igm Biosciences Inc Modified j-chain
SG10202001779UA (en) 2015-01-20 2020-04-29 Igm Biosciences Inc Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
SG11201707144VA (en) * 2015-03-04 2017-09-28 Igm Biosciences Inc Cd20 binding molecules and uses thereof
AU2016238246B2 (en) 2015-03-25 2021-05-13 Igm Biosciences, Inc. Multi-valent hepatitis B virus antigen binding molecules and uses thereof
CN107847591B (zh) 2015-04-17 2023-07-28 Igm生物科学股份有限公司 多价人免疫缺陷病毒抗原结合分子及其应用
EP3355913A1 (en) 2015-09-30 2018-08-08 IGM Biosciences A/S Binding molecules with modified j-chain
EP3356401B1 (en) 2015-09-30 2020-06-24 IGM Biosciences, Inc. Binding molecules with modified j-chain
KR102343742B1 (ko) 2016-05-09 2021-12-24 아이쥐엠 바이오사이언스 인코포레이티드 항-pd-l1 항체
IL302488A (en) * 2016-08-15 2023-06-01 Novartis Ag Dosing regimens and methods for the treatment of multiple sclerosis using opatumumab
US20200095327A1 (en) * 2017-02-08 2020-03-26 Dragonfly Therapeutics, Inc. Antibody heavy chain variable domains targeting the nkg2d receptor
WO2018148445A1 (en) 2017-02-08 2018-08-16 Adimab, Llc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
KR20240060739A (ko) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
EP3607091A4 (en) 2017-04-07 2021-01-20 IGM Biosciences, Inc. MODIFIED HUMAN CONSTANT IGM REGIONS FOR THE MODULATION OF COMPLEMENT-DEPENDENT CYTOLYSIS EFFECTOR FUNCTION
CA3237846A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
KR20200128391A (ko) 2018-03-01 2020-11-12 아이쥐엠 바이오사이언스 인코포레이티드 IgM 혈청 반감기에 영향을 미치는 IgM Fc 및 J-쇄 돌연변이
EP3880714A4 (en) * 2018-11-16 2022-07-20 Memorial Sloan Kettering Cancer Center ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体***
CN114181318B (zh) * 2021-11-08 2023-08-01 四川大学 一种组织特异性表达穿透血脑屏障的idua融合蛋白的重组腺相关病毒及应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5124471A (en) 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5417972A (en) 1993-08-02 1995-05-23 The Board Of Trustees Of The Leland Stanford Junior University Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US6962979B1 (en) 1995-03-14 2005-11-08 Cohesion Technologies, Inc. Crosslinkable biomaterial compositions containing hydrophobic and hydrophilic crosslinking agents
US5855911A (en) 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6680335B2 (en) 1998-09-28 2004-01-20 Sugen, Inc. Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
CZ2002936A3 (cs) 1999-09-17 2002-10-16 Abbott Gmbh & Co. Kg Pyrazolopyrimidiny jako terapeutické prostředky
US20020028178A1 (en) 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US7319139B2 (en) 2001-01-29 2008-01-15 Biogen Idec, Inc. TAG-72 specific CH2 domain deleted antibodies
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
CA2476625A1 (en) * 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
EP1682179A4 (en) 2003-11-05 2008-09-03 Palingen Inc INCREASED CYTOTOXICITY OF CDIM BINDING ANTIBODY AGAINST B LYMPHOCYTES
US20120237441A9 (en) * 2003-11-05 2012-09-20 Bhat Neelima M Enhanced b cell cytotoxicity of cdim binding antibody
AU2005304973A1 (en) * 2004-11-05 2006-05-18 Palingen, Inc. Antibody induced cell membrane wounding
EP1861424B1 (en) * 2005-03-14 2011-03-30 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Human monoclonal antibodies against hendra and nipah viruses
AU2006292132A1 (en) * 2005-09-19 2007-03-29 Palingen, Inc. Treatment of B cell diseases using anti-germline antibody binding agents
MX2009010765A (es) * 2007-04-02 2009-10-26 Amgen Fremont Inc Anticuerpos anti-ige.

Also Published As

Publication number Publication date
EP2812356A2 (en) 2014-12-17
JP2015511817A (ja) 2015-04-23
US9409976B2 (en) 2016-08-09
ES2735289T3 (es) 2019-12-17
CN104254544A (zh) 2014-12-31
HK1205136A1 (en) 2015-12-11
CN104254544B (zh) 2017-04-26
WO2013120012A2 (en) 2013-08-15
IN2014MN01781A (es) 2015-07-03
CA2863714A1 (en) 2013-08-15
JP6335796B2 (ja) 2018-06-06
TW201345921A (zh) 2013-11-16
AU2013200903B2 (en) 2015-05-14
AU2013200903A1 (en) 2013-08-22
BR112014019459A2 (pt) 2017-06-27
BR112014019459A8 (pt) 2023-01-10
CA2863714C (en) 2022-07-05
KR102102111B1 (ko) 2020-04-20
BR112014019459B1 (pt) 2023-04-18
US20140044739A1 (en) 2014-02-13
KR20150001728A (ko) 2015-01-06
MX363819B (es) 2019-04-03
EP2812356B1 (en) 2019-03-27
TWI606064B (zh) 2017-11-21
DK2812356T3 (da) 2019-07-08
WO2013120012A3 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
MX2014009628A (es) Uniones a cdim y sus usos.
PH12019500440A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MX349096B (es) Anticuerpos anti-pd-l1 y sus usos.
TR201910103T4 (tr) Anti-fcrn antikorları.
MX2015006374A (es) Anticuerpos anti-ceacam5 y usos de los mismos.
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
MX2020012426A (es) Anticuerpos anti-cd38.
MX2019006411A (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos.
PH12018500639A1 (en) Optimized monoclonal antibodies agaist tissue factor pathway inhibitor (tfpi)
MX2014008963A (es) Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
BR112014029099A2 (pt) anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende
MY156286A (en) Human il-23 antigen binding proteins
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
IN2014CN04645A (es)
NZ630864A (en) Use of semaphorin-4d binding molecules to promote neurogenesis following stroke
PH12020550598A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
WO2014100857A8 (en) Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
WO2012119989A3 (en) Antibodies against cadmi for the diagnosis and treatment of cancer
WO2012009640A3 (en) B cell depletion for central nervous system injuries and methods and uses thereof
WO2013040547A3 (en) Compounds and methods of immunization with tumor antigens
TN2013000265A1 (en) Anti-cd38 antibodies
NZ624876A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: IGM BIOSCIENCES INC.

GB Transfer or rights

Owner name: IGM BIOSCIENCES INC.

FG Grant or registration